KYZATREX “Practice in a Box”

**Canned Email Announcement**

**Version 1:** Patients Currently on TRT

**Use:** Partnering providers can utilize this content to announce to their patients who are currently taking some form of TRT that they now offer/recommend KYZATREX as a possible alternative.

**Subject line:**

* Explore an alternative form of TRT with KYZATREX® (testosterone undecanoate) CIII capsules

KYZATREX® (testosterone undecanoate) CIII capsules is an oral testosterone treatment for adult men who have low or no testosterone levels due to certain medical conditions.

Please see Important Safety Information, including Boxed Warning, below and accompanying Full [Prescribing Information](https://www.kyzatrex.com/pi/).

Hi [Patient’s Name],

At [Your Practice or Clinic Name], we strive to provide the best care and most effective treatment options for low testosterone. [I/We] understand that traditional testosterone replacement therapies like injections, pellets, or gels can sometimes be inconvenient or uncomfortable.

[I’m/We are] pleased to let you know about an alternative option that may interest you: FDA-approved KYZATREX, a twice-daily oral form of TRT that eliminates the need for injections and the mess of gels.

**Why Consider Switching to KYZATREX?**

* **Proven to Boost Testosterone:** KYZATREX has been shown to be up to 96% effective1,2\* in clinical studies, ensuring that your testosterone levels are maintained within the normal range.
* **Natural Rhythm Matching:** As an immediate-release medication taken twice daily, KYZATREX matches the body’s natural diurnal rhythm of testosterone production.
* **Reduced Complications:** No cases of erythrocytosis were observed in clinical studies, meaning there is less chance of needing to give blood due to high hematocrit levels.
* **Demonstrated Safety:** In a clinical study of 155 patients, the most common adverse event was high blood pressure (observed in 2.6% of patients taking KYZATREX).1

\*In a six-month clinical trial of 139 men with low testosterone, 88% of patients had normal testosterone levels at Day 90 (worst-case scenario calculation, excluding Site 104). Based on patients who completed the study (n=127), 96% of patients achieved normal testosterone levels at Day 90.

[Click here to learn more about KYZATREX.](https://www.kyzatrex.com/)

If you’re interested, let’s discuss how KYZATREX could fit into your treatment plan during your next visit. Please call our office at [phone number] to schedule an appointment.

Wishing you well,

[Your Name]

[Your Practice or Clinic Name]

[Contact Information]

[Practice or Clinic Logo]

***[INCLUDE PATIENT-FACING ISI]***

**References:**

1. KYZATREX [prescribing information]. Raleigh, NC: Marius Pharmaceuticals; 2022.
2. Bernstein JS, Dhingra OP. A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. *Ther Adv Urol*. 2024;16:1-17. 2024;doi:10.1177/17562872241241864